杭州1类创新药瑞玛比嗪注射液获批上市

Group 1 - The National Medical Products Administration has officially approved the listing of the innovative drug Remabipine Injection developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd [1] - Remabipine Injection acts as a contrast agent for kidney imaging, enabling more accurate assessment of kidney function and providing better diagnostic solutions for kidney disease patients [1] - The approval of Remabipine Injection reflects the implementation of measures to accelerate the high-quality development of the biopharmaceutical industry in Hangzhou, showcasing the effectiveness of regulatory support and service empowerment [1] Group 2 - Hangzhou has been deepening the "streamlining administration and delegating power" reform to create a favorable innovation ecosystem for biopharmaceutical companies [2] - The establishment of a dynamic monitoring mechanism for innovative product demands provides customized guidance for enterprises, while the "Enterprise Reporting Platform" simplifies the application process [2] - The market regulatory department in Hangzhou aims to continue enhancing review and approval reforms to accelerate the benefits of more innovative outcomes for patients, contributing to the establishment of a health science and technology innovation hub in Hangzhou [2]